Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (14219)	7/24/2000 5:29:04 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Robert, I hope it does not take ten years but my estimate includes a large trial and approval process. LLY probably would not want to do any talking until Protein C is approved. That is still about one year away. Why should they want to talk now, when there is no risk BPI will beat Protein C to approval for sepsis. (Has some remaining chance of approval for meningococcemia). That might be enough to drive LLY to talk now but sort of doubt it. Should be easy to understand why one would rather deal with ones approved drug in combination with an unapproved one. Am frankly not at all understanding the desire to make it seem like the psoriasis trial will finish so soon when just the treatment phase totals 2 periods of 12 weeks. Again, I hope all that think it will end sooner are right but prefer to be more conservative seeing how much longer everything takes than one first thinks it will.